Browse Articles
Discover research articles across all indexed journals
Study on mechanical properties and energy evolution laws of layered sandy slate
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Synergistic integration of regional and systemic therapies in uveal melanoma
Toward a Unified Mechanistic Understanding of Polymer Electrolytes for Advanced Solid‐State Batteries
ABSTRACT Polymer electrolytes (PEs) are widely regarded as a promising platform for solid‐state batteries (SSBs), offering the potential to simultaneously achieve high energy density with improved safety. However, in current literature, PEs spanning liquid‐percolated gels, liquid‐assisted quasi‐solids, and truly polymer‐governed solids are often indiscriminately grouped as solid polymer electrolytes (SPEs), obscuring their distinct ion transport mechanisms, interfacial behaviors, and practical performance constraints, and leading to misleading performance comparisons and unrealistic expectations regarding solid‐state operation. Herein, we establish a mechanistic framework that categorizes PEs into gel polymer electrolytes (GPEs), quasi‐solid polymer electrolytes (QSPEs), and all‐solid polymer electrolytes (ASPEs) based on their dominant ion‐solvation environment and transport pathways. By systematically analyzing the ion‐transport mechanisms, interfacial behaviors, and performance‐limiting features associated with each PE class, we clarify their defining characteristics and mechanism‐imposed limitations. Accordingly, we outline category‐specific research priorities and highlight the necessity of mechanism‐driven materials design, transparent definitions and reporting, and application‐relevant benchmarking. This unified Perspective lays a foundation for consistent interpretation, meaningful comparison across PE systems, and more rational materials design toward the advancement of PE‐enabled SSBs.
Parasite-specific essential bromodomain protein TgBDP4 is a key epigenetic reader and a potential drug target for the parasite Toxoplasma gondii
Glycosylation signature to predict response to immune checkpoint blockade in lung cancer.
272 Background: Immune checkpoint blockade (ICB) has improved long-term survival in non-small cell lung cancer (NSCLC); however, most patients do not achieve durable benefit. Current biomarkers, including PD-L1 immunohistochemistry and tumor mutation burden, provide limited predictive accuracy. Although transcriptomic signatures of immune infiltration and exclusion correlate with response, they largely focus on the tumor microenvironment. We hypothesized that integrating cancer-intrinsic transcriptional programs with immune contextures would better capture tumor-immune interactions and improve predictions of ICB response. Methods: We assembled transcriptomic and clinical data of 818 tumors across nine ICB-treated NSCLC cohorts, including an in-house sequenced cohort of 51 late stage patients, generating one the largest response-annotated whole-transcriptome NSCLC datasets to date. We systematically identified NSCLC-specific transcriptional programs associated with ICB response, and characterized their clinical and genomic correlates in > 1,100 TCGA NSCLC tumors. We developed a multivariate predictive model integrating cancer-intrinsic and immune features, and evaluated performance across five independent validation cohorts, benchmarking against established biomarkers. Results: We uncovered a glycosylation-associated transcriptional program linked to ICB resistance, characterized by low tumor mutation burden, reduced PD-L1 expression, and decreased T-cell infiltration, consistent with an immune-cold tumor state. Tumors with high glycosylation additionally upregulated alternative inhibitory checkpoint ligands, suggesting reliance on non-PD-L1 immune evasion mechanisms to maintain immune exclusion. Integrating glycosylation and immune infiltration features, we developed IOSelect-lung , which robustly stratified ICB outcomes. Across five independent test cohorts, IOSelect-lung achieved a mean AUC of 0.77, significantly outperforming existing signatures (AUC 0.39-0.65). The model was predictive in the ICB arm but not in the chemotherapy control arm, indicating treatment-specific predictive value rather than general prognostic association. In joint analyses incorporating clinicopathological and hematological variables, IOSelect-lung demonstrated predictive power beyond established clinical and molecular biomarkers. Conclusions: A cancer-intrinsic glycosylation program defines an immune-cold, ICB-resistant subset of NSCLC. We introduced IOSelect-lung , a parsimonious model that reflects NSCLC-specific tumor biology and provides treatment specific predictive value beyond current biomarkers. These findings highlight glycosylation pathways and alternative checkpoints as potential therapeutic vulnerabilities, and support the development of cancer-type-specific biomarkers to improve patient stratification for ICB.
Identification of novel CD8+ immune epitopes relevant for EBV-related cancers.
88 Background: EBV infects 95% of the world’s population and is associated with EBV related cancers that include Asian prevalent nasopharyngeal carcinoma (NPC) amongst others. Asian HLA restricted EBV viral immune epitope target identification and specifically CD8 epitopes continue to be an unmet need that requires to be addressed with novel methods to inform downstream vaccine development. Methods: Firstly, a lead protein latent membrane protein 2 (LMP2) was identified from 72 proteins on the basis of high: i) expression; ii) predicted immunogenicity; and iii) conservation across EBV strains. Secondly, HLA-A*11:01 restricted peptides predicted in silico (NetMHCPan4.1) identified 7 peptides from three predicted immunogenic regions, then, focusing on a single most immunogenic region only (highest number and affinity in silico predictions), predicted high affinity peptides were experimentally validated using proprietary biophysical peptide MHC binding assay, EZ-MHC. Thirdly, this region was interrogated for additional novel unpredicted immunogenic peptides. Results: A comprehensive 50 peptide panel ranging from 8-14 mer across this single region was designed, peptides procured then tested for experimental peptide HLA-A*11:01 binding (EZ-MHC). Of the 50 peptides screened, 11 novel, in silico unpredicted, EBV LMP2 stable binding peptides were identified from this single region. Conclusions: Additional novel CD8 epitopes were found with unbiased interrogation of peptides derived from a single region that was predicted to be most immunogenic on EBV LMP2 identifying novel lead targets. Further downstream functional validation of these novel targets will further identify the best putative peptide vaccine candidates. These can potentially be harnessed as therapeutic CD8 T cell directed peptide vaccines for not only EBV NPC patients but also patients with other EBV related cancers.
Correspondence on “Fortification of FeS Clusters Reshapes Anaerobic CO Dehydrogenase Into an Air‐Viable Enzyme Through Multilayered Sealing of O <sub>2</sub> Tunnels”
ABSTRACT In their recent communication in Angewandte Chemie ( 10.1002/anie.202508565 ), Suk Min Kim and coworkers have described the effect of modifying the gas channels of the CO dehydrogenase II from Carboxydothermus hydrogenoformans , an enzyme that oxidizes reversibly CO into CO 2 . Their goal was to use mutagenesis to slow down the arrival of O 2 at the active site. They reported a large increase in the resistance against oxygen, one of the major barriers to the application of this extremely fast and efficient enzyme in biotechnological devices, with an increase in the IC 50 of more than two orders of magnitudes for some variants, with only a minor impact on the affinity of the enzyme for CO. We have produced the same variants, and characterized them in depth using Protein Film Electrochemistry. We used an approach that has proven very useful to learn and understand about the reactivity of CO dehydrogenases (and other redox enzymes like hydrogenases) with O 2 . We found that, contrary to the claims by Kim and coworkers, the A559W and the A559W/V610H mutants are not more resistant than the wild type against oxygen.
Superclonal expansion and barley yellow dwarf virus transmission failure in invasive Metopolophium festucae cerealium
Abstract Biological invasions can influence ecosystems, yet the evolutionary trajectories and disease dynamics of clonal expansion remain poorly understood. Since its 2011 detection, Metopolophium festucae cerealium (Stroyan), a subspecies of the cereal grass aphid endemic to Europe, has expanded across small grain growing regions of the western U.S. Our field surveys further indicate continued range expansion into previously unreported areas. Here, we integrate population genomics with virus transmission assays to evaluate its invasion structure and potential role in barley yellow dwarf virus (BYDV) transmission. Genome-wide SNP analysis of 262 individuals from six states reveals high genetic homogeneity, supporting a single introduction event and subsequent superclonal expansion. Although M. f. cerealium acquires BYDV at rates comparable to native Rhopalosiphum padi and maintains similar viral titers, it fails to transmit the virus. The primary agroecological risk posed by this invasion is through direct feeding injury, underscoring the need for continued monitoring and refined pest management strategies.
First CD123-targeted ADC secures FDA approval for rare blood cancer
The clinical landscape of HIF2α inhibitors in oncology
A secreted endosymbiont protein essential for colonizing host cells
A Self‐Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy
ABSTRACT Sonodynamic therapy (SDT) generates reactive oxygen species (ROS) for noninvasive, spatiotemporally controlled tumor therapy. However, whether ROS‐driven stress also reprograms tumor immune signaling toward immune resistance, thereby limiting durable antitumor immunity, remains unclear. This study reveals that immune resistance is a universal mechanism shared by three major classes of clinically used SDT sensitizers. A porphyrin‐biguanide‐loaded albumin nanoparticle (POR‐BG@Alb) is rationally developed as a self‐immunoregulatory sonosensitizer, which induces mitochondrial dysfunction to activate AMP‐activated protein kinase (AMPK) and suppress c‐MYC, concomitantly downregulating PD‐L1 and CD47 and enhancing T‐cell killing and macrophage phagocytosis. Unlike clinically used traditional sensitizers that upregulate PD‐L1/CD47 after SDT and promote innate and adaptive immunosuppression, POR‐BG@Alb amplifies sonodynamic efficacy while limiting this feedback. Across orthotopic bladder cancer, subcutaneous xenograft, and orthotopic breast cancer models, POR‐BG@Alb‐mediated SDT suppresses primary tumors, elicits abscopal antimetastatic effects, establishes immune memory, and extends median survival in subcutaneous xenografts from 17 to 44 days. Collectively, this research unmasks a previously unappreciated role of SDT in inducing immune resistance and shows that POR‐BG@Alb integrates potent sonodynamic activity with self‐oxygen regulation and self‐immunoregulation to enable durable systemic antitumor immunity, providing a promising nanotherapeutic strategy for SDT clinical translation.
Breaking Symmetry via Bamboo‐Inspired Gradient Engineering for Triple‐Field Synergistic H <sub>2</sub> O <sub>2</sub> Production
ABSTRACT Piezocatalysis is a promising chemical synthesis technique, but it is generally restricted to noncentrosymmetric materials, severely limiting catalyst selection. The flexoelectric effect bypasses this symmetry constraint. However, its catalytic contribution is often overlooked, as conventional materials generate only modest strain gradients. Inspired by the hierarchical radial gradients in natural bamboo, we developed radial‐gradient BiO(Cl, Br) nanosheets. This architecture breaks the centrosymmetry of BiOCl to invoke robust piezoelectricity while simultaneously amplifying flexoelectricity through built‐in mechanical heterogeneity. Driven by a triple‐field synergism of built‐in, piezo‐, and flexoelectric fields, the BiO(Cl, Br) nanosheets achieve a high H 2 O 2 production rate of 742.2 µmol g −1 h −1 , approximately 423% of pristine BiOCl. Theoretical analysis reveals that the mechanical strain and Br doping synergistically modulate the work function and the p ‐band center, facilitating spin‐selective O 2 orbital coupling and reducing the activation barrier for superoxide formation. This work provides an effective strategy to break through symmetry constraints in piezocatalysis, paving the way for the rational design of high‐performance mechano‐catalysts through gradient engineering.
Basigin (CD147) and calpain 4 (CapnS1) are partners in the generation of traction force but not in mechanosensing
Cross-continental transportability of phase III trial results to LMIC cohort with locally advanced NSCLC: A g-computation analysis with layered decomposition.
276 Background: Clinical trial results are frequently extrapolated to populations that were never part of Western RCTs, such as those in lower- and middle-income countries (LMIC), yet formal testing of transportability is almost never performed. We performed a causal transportability analysis to determine if survival predictions from the RTOG 0617 trial generalize to an LMIC cohort. Methods: We harmonised individual patient data from RTOG 0617 (n=258, 60Gy and 74Gy chemoradiation arms, without cetuximab) and a single-institution cohort (n=123) for stage IIIA–IIIB NSCLC. The Indian cohort was restricted to ECOG 0–1 and standard platinum-doublet chemotherapy resulting in 91 patients. The overall survival (OS) restricted mean survival time (RMST) gap at 24 months served as the primary transportability metric, quantified as transported minus observed RMST. We used G-computation with bootstrap shrinkage-corrected Western Cox models using a parsimonious set of harmonizable clinical covariates (age, ECOG, histology, stage, consolidation chemotherapy), to predict outcomes in the Indian cohort. We employed layered decomposition to isolate baseline hazard contributions from covariate effects. Calibration was assessed via slopes and Expected-to-Observed (E/O) ratios. Robustness was tested via three pre-specified sensitivity analyses (SA): SA1 restricted the source to the 60 Gy arm; SA2 removed consolidation chemotherapy; and SA3 added sex and radiotherapy technique (IMRT vs 3D-CRT). Results: Substantial covariate imbalances existed between cohorts (standardised mean differences >0.50 for age, ECOG, smoking, stage, and consolidation). In the primary analysis, the 24-month OS RMST gap was −1.5 months (95% CI −6.8 to +1.7, p=0.412)(observed = 19.2 months, transported = 17.7 months), suggesting plausible exchangeability. However, the E/O ratio of 1.35 indicated the Western model over-predicted Indian mortality by 35%. Sensitivity analyses revealed this result was fragile. Restricting to the 60 Gy arm (SA1) widened the OS gap to −3.6 months (95% CI −10.0 to +0.7, p=0.132). Removing consolidation (SA2) resulted in a collapsed model [calibration slope deviation (7.95, p=0.025)], confirming that consolidation chemotherapy acted as a confounder masking true population differences. Adding IMRT and gender (SA3) pushed the OS gap to near-significance (−2.9 months, 95% CI −6.8 to +0.1, p=0.060). The OS RMST gap was negative in all four analyses, with p-values tightening monotonically as compensatory modelling features were removed. Conclusions: NSCLC trial data provide guidance but not quantitative predictions, and application of trial-derived prognostic tools in LMIC settings requires recalibration of outcome data. High quality registries and equitable access to IPD trial data are needed to support local prognostic model development.
CanAssist Breast in routine clinical care: A real-world single-centre experience.
49 Background: In Asian HR+/HER2- early-stage breast cancer (EBC) patients, data on prognostication using Western prognostic tests are limited and intriguing. To address this, CanAssist Breast (CAB), a proteomic-based prognostic test, was developed from Indian patients’ tumors and validated in multiple retrospective studies across India, the US, Europe, and in a completed, prospective-randomized TEAM trial in the Netherlands. CAB utilizes the expression of five biomarkers and three clinical parameters to categorize patients as ‘low-risk’ or ‘high-risk’ for distant recurrence within 5 years of diagnosis using an AI-based algorithm. CAB has been used as a prognostic tool to guide personalized adjuvant chemotherapy decisions since 2016. CAB is included in the treatment guidelines of the Asian Geriatric Oncology Society, the Indian Society of Medical and Paediatric Oncology, and the Association of Breast Surgeons of India. This study highlights our single-centre experience evaluating the impact of CAB on clinical decision-making. Methods: Data from 309 patients who underwent CAB testing at Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC), Delhi, between 2017 and January 2026 were compiled. We analysed CAB-based risk stratification across different clinical subgroups and assessed treatment adherence based on CAB results. Results: CAB stratified 49% patients as ‘low risk’ and 51% as ‘high risk’ for distant recurrence. The patients’ median age was 58 years. Of the total cohort, 65% were >50 years old, and 35% were ≤50 years old. T2 tumors constituted 80% of the cohort, followed by T1 tumors (20%). Of the total cohort, 6% of patients presented with G1 tumors, while 53% had G2, and 41% had G3 tumors. 61% and 39% of patients were node-negative (N0) and node-positive (N+), with low- and high-risk proportions of 65:35 and 24:76, respectively. Treatment information was available for 267 (86%) patients; 100% of low-risk patients did not receive chemotherapy, whereas 91% of high-risk patients did. The overall treatment adherence was 96%. Notably, in patients conventionally considered clinically high-risk, the low- and high-risk treatment adherence (%) was as follows: ≤50 years, 100:98; N+, 100:90, respectively. Conclusions: CAB effectively stratifies patients into low- and high-risk categories for distant cancer recurrence, helping the low-risk patients in this cohort avoid chemotherapy even when presented with clinically high-risk features. This demonstrates the utility of CAB as a decision-making prognostic test in our study cohort, supporting that CAB serves as a cost-effective, ideal alternative to Western prognostic tests for HR+/HER2- EBC patients.